戻る Agenda
Session 8: Management of Commercially Confidential Information (CCI) in Clinical Trial Applications (CTA) under the EU Clinical Trial Regulation (CTR)
Session Chair(s)
Lora Killian, MBA
Clinical Trial Transparency and Disclosure Lead
Pfizer, United States
Thomas Schindler, PHD
Director Global Regulatory Affairs - Regulatory Operations
BioNTech SE, Germany
Session 8: Management of Commercially Confidential Information (CCI) in Clinical Trial Applications (CTA) under the EU Clinical Trial Regulation (CTR)
Speaker(s)
Risks posed by CTIS to the protection of clinical trial innovation
Polyana Bastos
Actelion Pharmaceuticals, Switzerland
Senior Director, Regulatory Law
CCI management in EU Clinical Trial Applications
Lora Killian, MBA
Pfizer, United States
Clinical Trial Transparency and Disclosure Lead
CCI management in EU Clinical Trial Applications
Wendy M Wimmer, MS
Merck & Co., Inc., United States
Director, Clinical Data Disclosure and Transparency